Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Deciphera Pharmaceuticals, LLC
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Novartis
National Institutes of Health Clinical Center (CC)